Higher disease activity and systemic inflammation at baseline associated with greater risk of MACE in bDMARD nonusers but not in users. bDMARD-specific benefits directly on MACE risk beyond reducing inflammation, Karpouzas et al Abst#0391 #ACR23 @RheumNow https://t.co/lfoccZffTW https://t.co/ASpKYQof1I